Michael Mahoney Sells 160,901 Shares of Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation (NYSE:BSX) CEO Michael Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Boston Scientific Stock Down 17.6%

Shares of NYSE:BSX opened at $75.50 on Thursday. The firm has a market capitalization of $111.92 billion, a PE ratio of 40.37, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67. The business has a 50 day simple moving average of $94.37 and a two-hundred day simple moving average of $99.13. Boston Scientific Corporation has a 1 year low of $75.00 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period last year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat on both EPS and revenue; revenue grew ~15.9% year-over-year, and margins improved — the underlying quarter was strong, showing continued organic growth across several franchises. Boston Scientific announces results for fourth quarter and full year 2025
• Neutral Sentiment: Analyst coverage and the company’s earnings materials/earnings call provide detail for valuation and segment trends — useful for investors who want to dig into segment-level drivers and management’s assumptions. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Management’s FY‑2026 guidance was modestly below or roughly in line with Street expectations (FY EPS range and revenue range came in light enough to reset growth assumptions), and Q1 guidance was cautious — that outlook is the main driver of the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Electrophysiology (one of Boston Scientific’s higher-growth, higher-profile segments) underperformed vs. expectations, which worried investors about near-term growth momentum in a key franchise. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
• Negative Sentiment: Unusually large put-option activity and heavy trading signaled short-term bearish positioning and hedging, amplifying downside pressure. BSX Earnings: Boston Scientific Stock Plunges on Weak Guidance
• Negative Sentiment: CEO insider selling (large block disclosed) adds to near-term negative sentiment even though insider transactions can be for many reasons. Insider sale SEC filing

Analyst Upgrades and Downgrades

BSX has been the subject of several research reports. Evercore ISI set a $112.00 price objective on shares of Boston Scientific in a research report on Monday, January 5th. UBS Group reiterated a “buy” rating on shares of Boston Scientific in a report on Wednesday, December 17th. Oppenheimer reduced their price objective on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, January 21st. Finally, Needham & Company LLC reissued a “buy” rating on shares of Boston Scientific in a research report on Thursday, January 15th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $121.84.

Institutional Trading of Boston Scientific

Hedge funds have recently bought and sold shares of the stock. Steph & Co. bought a new stake in Boston Scientific during the third quarter valued at about $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp boosted its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Finally, United Community Bank raised its stake in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.